Clinical biomarkers in hepatocellular carcinoma (HCC)

18Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

The Authors make a review of the most important molecules used today for detecting and screening hepatocellular carcinoma, analyzing their known biological features, advantages and limits especially concerning differential diagnosis from cirrhosis and others diseases. AFP, AFP-L3, DCP, Alpha-1-fucosidase are analyzed and all the current knowledge reviewed, as well as focusing on possible future applications and results of combined determination (what about another word here: evaluation etc) in HCC. Additionally other more recent molecules showing promising future clinical application are cited.

Cite

CITATION STYLE

APA

Donati, M., Brancato, G., & Donati, A. (2010, January 1). Clinical biomarkers in hepatocellular carcinoma (HCC). Frontiers in Bioscience - Scholar. Bioscience Research Institute. https://doi.org/10.2741/s86

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free